CNS Pharmaceuticals: approves 650,000-share increase to 2020 equity plan

What happened CNS Pharmaceuticals, Inc. reported that at its scheduled 2026 Annual Meeting of Stockholders the Company’s stockholders approved amendments to the Company's 2020 Equity Plan increasing the number of shares authorized for issuance under the 2020 Plan by 650,000 shares. As amended, the number of shares of common stock that may be issued under the 2020 Plan is 765,061 shares. The Proxy Statement relating to the Annual Meeting was filed on Aug 21, 2026.

Key details

• The stockholder vote approved an increase of 650,000 shares to the 2020 Equity Plan.
• After the amendment, the 2020 Equity Plan authorizes 765,061 shares for issuance.
• The Company referenced its definitive proxy statement filed with the SEC on Aug 21, 2026.
• The filing lists Item 5.02 (departure of directors or certain officers) and Item 5.07 (submission of matters to a vote of security holders).

Why it may matter The filing reports Item 5.07, which covers the submission of matters to a vote of security holders and, in this case, the vote approving the amendment to the 2020 Equity Plan. The filing also reports Item 5.02, which covers departures or elections of directors or certain officers. The filing does not show why the insider traded or why the company acted.